We are submitting herewith the copy of Business Responsibility and Sustainability Report of the Company for the financial year 2025-26.

Date: September 03, 2026 To, To, Sr. General Manager Sr. General Manager Listing Department Listing Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block G Dalal Street Bandra Kurla Complex Mumbai – 400 001 Bandra (E), Mumbai – 400 051 BSE Scrip Code: 544319 NSE Symbol: SENORES Dear Sir/Madam, Sub.: Business Responsibility and Sustainability Report of the Company for the Financial Year 2025-26 Pursuant to Regulation 34(2)(f) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we are submitting herewith the Business Responsibility and Sustainability Report of the Company for the Financial Year 2025-26. The aforesaid report is also available on Company’s website at https://senorespharma.com/reports1/. You are requested to take the same on record. Thanking you. For Senores Pharmaceuticals Limited Shilpa Sharma Company Secretary and Compliance Officer ICSI Membership No.: A34516 Encl.: As mentioned above Senores Pharmaceuticals Limited 1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad-380054, Gujarat, India P: +91 79 2999 9857 | E: info@senorespharma.com W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263 Business Responsibility and Sustainability Report for Financial Year ended 31 March 2026 SECTION A: GENERAL DISCLOSURES I. Details of the listed entity 1 Corporate Identity Number (CIN) : L24290GJ2017PLC100263 2 Name of the Company : Senores Pharmaceuticals Limited 3 Year of incorporation : 2017 4 Registered office address : 1101 to 1103, 11th Floor, South Tower, One42, Ambali Bopal Road, Ahmedabad-380054, Gujarat, India 5 Corporate address : 1101 to 1103, 11th Floor, South Tower, One42, Ambali Bopal Road, Ahmedabad-380054, Gujarat, India 6 E-mail : cs@senorespharma.com 7 Telephone : +91 79 29999857 8 Website : www.senorespharma.com 9 Financial year for which reporting is being done 2025-2026 10 Name of the Stock Exchange(s) where shares a) National Stock Exchange of India Limited are listed : b) BSE Limited 11 Paid-up Capital : 46,05,35,880 12 Name and contact details of the person Mrs. Shilpa Sharma who may be contacted in case of any queries Company Secretary & Compliance Officer on the BRSR report : cs@senorespharma.com +91 79 29999857 13 Reporting boundary - Are the disclosures under The disclosures made in this report are on a standalone basis. this report made on a standalone basis or on a consolidated basis? : 14 Name of assurance provider : Not Applicable 15 Type of assurance obtained : Not Applicable II. Products/services : 16. Details of business activities (accounting for 90% of the turnover) : % of Turnover of Sr. No. Description of Main Activity Description of Business Activity the entity Research & Development, Manufacturing, Marketing, 1 Manufacturing and sale of pharmaceutical products 100% and Distribution of Pharmaceutical Products 17. Products/Services sold by the entity (accounting for 90% of the entity’s Turnover): % of total Sr. No. Product/Service NIC Code Turnover contributed 1 Manufacture of pharmaceuticals, medicinal chemical and botanical 21.54% 2100 products. 2 Wholesale of pharmaceutical and medical goods 46.92% 46497 3 Management consultancy activities 8.16% 7020 4 Research and experimental development on natural sciences and 22.49% engineering 7210 III. Operations: 18. Number of locations where plants and/or operations/offices of the entity are situated: Location Number of plants Number of offices Total National 2 5 7 International - - - 19. Markets served by the entity: a. Number of locations: Locations Number National (No. of States) Pan India International (No. of Countries) 6 b. What is the contribution of exports as a percentage of the total turnover of the entity? Contribution of exports is 43.95% of our total turnover during the financial year 2025-26. c. A brief on types of customers Senores Pharmaceuticals Limited ('the Company) primarily operates as a B2B pharmaceutical developer and manufacturer. Its key customers include major Indian and global pharmaceutical companies and distribution partners that distribute its specialty generic medicines, as well as healthcare providers and patients in India and certain overseas markets. IV. Employees: 20. Details as at the end of Financial Year: a. Employees and workers (including differently abled): Sr. Total Male Female Particulars No. (A) No. (B) % (B / A) No. (C) % (C / A) EMPLOYEES 1. Permanent (D) 324 283 87% 41 13% 2. Other than Permanent (E) 5 5 100% - 0% 3. Total employees (D + E) 329 288 88% 41 12% WORKERS 4. Permanent (F) 42 42 100% - 0% 5. Other than Permanent (G) 69 69 100% - 0% 6. Total workers (F + G) 111 111 100% - 0% b. Differently abled Employees and workers: Sr. Total Male Female Particulars No. (A) No. (B) % (B / A) No. (C) % (C / A) DIFFERENTLY ABLED EMPLOYEES 1. Permanent (D) - - 2. Other than Permanent (E) - - Total differently abled employees (D + 3. - - - - - DIFFERENTLY ABLED WORKERS 4. Permanent (F) - - 5. Other than permanent (G) - - 6. Total differently abled workers (F + G) - - - - - 21. Participation/Inclusion/Representation of women No. and percentage of Females Particulars Total (A) No. (B) % (B / A) Board of Directors * 12 1 8% Key Management Personnel ** 2 - - *includes both Independent and Non Independent Directors ** Key Management Personnel other than Board of Directors 22. Turnover rate for permanent employees and workers (Disclose trends for the past 3 years) Particulars FY 2025-26 FY 2024-25 FY 2023-24 Male Female Total Male Female Total Male Female Total Permanent Employees 18.72% 18.18% 18.64% 13.63% 23.52% 15.66% 17.40% 18.20% 17.60% Permanent Workers 12.19% 0.00% 12.19% 8.33% 0.00% 8.33% 0.00% 0.00% 0.00% V. Holding, Subsidiary and Associate Companies (including joint ventures) 23. Names of holding / subsidiary / associate companies / joint ventures Sr. No. Name of the holding /subsidiary/ associate companies/ Indicate whether holding/ % of shares held by Does the entity indicated at column joint ventures (A) Subsidiary/ Associate/ Joint listed entity A, participate in the Business Venture Responsibility initiatives of the listed entity? (Yes/No) 1 Havix Group Inc. D/B/A Aavis Pharmaceuticals Subsidiary 57.69% No 2 Apnar Pharma Pvt. Ltd. Subsidiary 75.00% No 3 Ratnatris Pharmaceuticals Pvt. Ltd. Subsidiary 69.00% No 4 Senores Pharmaceuticals Inc Subsidiary 100.00% No VI. CSR Details 24. (i) Whether CSR is applicable as per section 135 of Companies Act, 2013: (Yes/No) - YES (ii) Turnover: INR 10,609 lakhs (iii) Net worth : INR 74,990 lakhs VII. Transparency and Disclosures Compliances 25. Complaints/Grievances on any of the principles (Principles 1 to 9) under the National Guidelines on Responsible Business Conduct: Grievance Redressal FY 2025-26 FY 2024-25 Mechanism in Place (Yes/No) Stakeholder group from whom complaint is Number of Number of (If Yes, then Number of received Number of complaints complaints provide web- complaints complaints filed pending Remarks pending resolution Remarks link for filed during during the year resolution at at close of the grievance the year close of the year year redress policy) Communities Yes - - - - - Investors (other than shareholders) Yes - - - - - Shareholders Yes - - - - - Employees and workers Yes - - - - - Customers Yes - - - - - Value Chain Partners Yes - - - - - The Company has a grievance redressal mechanism in place for all internal and external stakeholders of the business. 26. Overview of the entity’s material responsible business conduct issues: Sr. No. Material issue identified Indicate Rationale for identifying the In case of risk, approach to adapt or Financial implications of the risk or whether risk or risk/opportunity mitigate opportunity (Indicate positive or opportunity negative implications) (R/O) 1 Climate change R Climate change presents operational The Comp [Showing first 8,000 characters — download PDF for full document]